mRNA Vaccine Technology: Development and Future Potential
TOPIC CLASSIFICATION
Subject: Science & Technology Sub-area: Biotechnology / Healthcare Prelim PYQ Trend: High (post-COVID surge in questions) Mains Relevance: GS-3 (Science & Technology, Health)
EXAMINER REASONING
mRNA vaccine technology became a UPSC favourite after the COVID-19 pandemic. The examiner tests: (a) mechanism — how mRNA vaccines work (vs traditional vaccines); (b) advantages — speed of development, adaptability, platform technology; (c) India's role — Zydus Cadila DNA vaccine, Gennova mRNA vaccine (India's first mRNA vaccine), manufacturing capacity; (d) future applications — cancer vaccines, HIV, malaria, personalised medicine; (e) challenges — cold chain storage (ultra-low temp), vaccine hesitancy, funding. Expect questions comparing vaccine platforms (viral vector, inactivated, mRNA).
Core Concept
What is mRNA Technology? mRNA (messenger RNA) vaccines use synthetic mRNA to instruct cells to produce a target antigen (e.g., spike protein of SARS-CoV-2), triggering an immune response without using live or inactivated virus.
How mRNA Vaccines Work:
- Synthetic mRNA encoding antigen is encapsulated in lipid nanoparticles (LNPs)
- LNP delivers mRNA into host cells (usually muscle cells)
- Ribosomes translate mRNA into spike protein
- Spike protein displayed on cell surface → immune system recognises it
- B-cells produce antibodies, T-cells develop memory
Advantages over Traditional Vaccines:
- Speed: mRNA vaccines developed in 10 months (traditional: 5-10 years)
- Platform: Same technology can be quickly adapted to new variants/antigens
- Safety: No live virus — no risk of infection; mRNA degrades naturally
- Scalability: In vitro transcription (IVT) — cell-free manufacturing, rapid scale-up
- Cell-mediated immunity: Induces both humoral (antibody) and cellular (T-cell) response
Disadvantages/Challenges:
- Cold Chain: Requires -20°C to -70°C storage (Pfizer-BioNTech: -70°C; Moderna: -20°C)
- Reactogenicity: Higher rates of fever, fatigue, headaches compared to traditional vaccines
- Novelty: Public skepticism; misinformation (microchips, DNA alteration myths)
- Cost: Higher cost per dose than adenoviral or inactivated vaccines (but decreasing with scale)
Global Development: